Xadago for Parkinson’s disease (PD) is now available in 14 European countries through partner, Zambon. Additionally, the drug is available in the US market (launched in H217 by sublicensee US WorldMeds). Newron reported revenues of €13.4m in FY17 (+100%) driven by royalty and milestone payments for Xadago and an operating loss of €4.3m (-71%). We expect pipeline progression in FY18: sarizotan (Rett’s syndrome, RS) and Evenamide (schizophrenia) highlight a diverse and inn
04 Apr 2018
Newron Pharmaceuticals - 2018 focus on the CNS pipeline
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Newron Pharmaceuticals - 2018 focus on the CNS pipeline
Newron Pharmaceuticals S.p.A. (NWRN:SWX) | 0 0 0.0%
- Published:
04 Apr 2018 -
Author:
Dr Susie Jana -
Pages:
8
Xadago for Parkinson’s disease (PD) is now available in 14 European countries through partner, Zambon. Additionally, the drug is available in the US market (launched in H217 by sublicensee US WorldMeds). Newron reported revenues of €13.4m in FY17 (+100%) driven by royalty and milestone payments for Xadago and an operating loss of €4.3m (-71%). We expect pipeline progression in FY18: sarizotan (Rett’s syndrome, RS) and Evenamide (schizophrenia) highlight a diverse and inn